PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

• ClinicalTrials.gov Identifier: NCT02288897
• Recruitment Status: Terminated
• First Posted: November 11, 2014
• Last Update Posted: October 2, 2019
• Sponsor: Provectus Biopharmaceuticals, Inc.
• Information provided by (Responsible Party): Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )

Tracking Information

• First Submitted Date: November 4, 2014
• First Posted Date: November 11, 2014
• Last Update Posted Date: October 2, 2019
• Actual Study Start Date: April 2015
• Actual Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: November 7, 2014): Progression-free survival (PFS) [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Original Primary Outcome Measures: Same as current
• Change History: Complete list of historical versions of study NCT02288897 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures (submitted: March 11, 2015)

• Complete response rate (CRR) [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Duration of complete response [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Overall survival (OS) [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Number of participants with adverse events [ Time Frame: Assessed every 4 weeks until 28 days after last treatment ]
  Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs.

Original Secondary Outcome Measures (submitted: November 7, 2014)

• Complete response rate (CRR) [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Duration of complete response [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Change in total symptom score from baseline using the patient reported Skindex-16 instrument [ Time Frame: Assessed 12 weeks after Day 1 ]
• Overall survival (OS) [ Time Frame: Assessed every 12 weeks up to 18 months ]
• Number of participants with adverse events [ Time Frame: Assessed every 4 weeks until 28 days after last treatment ]
  Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs.

• Current Other Pre-specified Outcome Measures (submitted: March 11, 2015): Change in domain scores from baseline using the patient reported Skindex-16 instrument [ Time Frame: Assessed 12 weeks after Day 1 ]
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
• Official Title: PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
• Brief Summary: This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine (DTIC), temozolomide (TMZ) or intralesional talimogene laherparepvec as determined by Investigator preference and standard of care in the Investigator's country or region. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms.

Detailed Description

Subjects will be randomized using a 2:1 treatment allocation (i.e. two-thirds of the subjects will receive PV-10).

Subjects in the comparator arm who have completed at least 1 cycle of study treatment and who meet the study protocol definition of disease progression but do not have evidence of visceral metastases will be eligible to enter the crossover portion of the study and receive PV-10. Subjects crossing over must meet all study inclusion and exclusion criteria for clinical laboratories, thyroid function, concurrent or intercurrent illness and pregnancy at the time of crossover.

Assessment of progression will be performed by an Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 criteria. Events signaling progression include increase in size and/or number of lesions, distant or nodal disease progression, or death. All secondary endpoints involving disease response and progression will be based on the IRC determination.

An interim assessment of efficacy and safety will be performed by the IRC when 50% of the events required for the primary endpoint have occurred.

• Study Type: Interventional
• Study Phase: Phase 3

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:

Blinded review by independent review committee (IRC) for primary and key secondary endpoints.

Primary Purpose: Treatment

• Condition: Cutaneous Melanoma

Intervention

• Drug: PV-10 (10% rose bengal disodium)
• Drug: Dacarbazine, temozolomide or talimogene laherparepvec

Study Arms

• Experimental: PV-10
  Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
  Intervention: Drug: PV-10 (10% rose bengal disodium)
• Active Comparator: Chemotherapy or Oncolytic Viral Therapy
  Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
  Intervention: Drug: Dacarbazine, temozolomide or talimogene laherparepvec

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: September 30, 2019): 32
• Original Estimated Enrollment (submitted: November 7, 2014): 225
• Actual Study Completion Date: September 2019
• Actual Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Age 18 years or older, male or female
2. Histologically or cytologically confirmed melanoma
3. Recurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., AJCC Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases)

4. At least 1 measurable Target Lesion that can be accurately measured by calipers or computed tomography (CT) consisting of:

   • at least one cutaneous lesion (each lesion ≥ 10 mm in longest diameter or up to 5 lesions having a sum of longest diameters ≥ 10 mm); and/or
   • at least one subcutaneous lesion (each lesion ≥ 10 mm in longest diameter by CT);
   • where Target Lesions should be at least 10 mm from any other lesion
5. No lesion > 50 mm in longest diameter; and no more than 50 lesions
6. Calculated required PV-10 dose ≤ 15 mL (based on total tumor burden)
7. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-2
8. Not a candidate for treatment with an immune checkpoint inhibitor (e.g., failed or did not tolerate prior therapy, or due to co-morbidities, pre-existing autoimmune disease, drug unavailability or standard of care)
9. Not a candidate for targeted therapy with BRAF or combined BRAF/MEK inhibitors (e.g., failed or did not tolerate prior therapy, BRAF V600 wild-type or due to drug unavailability or standard of care)

10. Clinical Laboratories:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L and platelet count ≥100 x 10^9/L
    • Creatinine ≤ 3 times the upper limit of normal (ULN)
    • Estimated creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
    • Total bilirubin ≤ 3 times the upper limit of normal (ULN)
    • Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal (ULN)
    • Lactate dehydrogenase (LDH) ≤ 2 times the upper limit of normal (ULN).
11. Thyroid function abnormality ≤ Grade 2

12. Candidate for at least one comparator drug:

    • Subjects must be candidates for at least one of the designated comparator drugs

Exclusion Criteria:

1. Presence or history of visceral melanoma metastasis
2. Presence of active nodal metastases (e.g., radiologic or clinical evidence of current nodal disease)
3. Presence of more than 50 melanoma lesions
4. Radiation therapy to any Study Lesion within 6 weeks of initial study treatment.
5. Chemotherapy or other systemic cancer therapy within 4 weeks of initial study treatment (6 weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within 12 weeks of initial study treatment
6. Immunotherapy for cancer within 4 weeks of initial study treatment
7. Local treatment (e.g., surgery, cryotherapy, laser ablation) to any Study Lesion within 4 weeks of initial study treatment
8. Anti-tumor vaccine therapy within 6 weeks of initial study treatment.
9. Investigational agents within 4 weeks of initial study treatment.

10. Concurrent or Intercurrent Illness:

    • Impaired wound healing or other extremity complications due to diabetes mellitus in subjects whose Study Lesions are located in an extremity
    • Severe peripheral vascular disease in subjects whose Study Lesions are located in an extremity
    • Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
    • Uncontrolled thyroid disease or cystic fibrosis
    • Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders

11. Pregnancy:

    • Female subjects who are pregnant or lactating
    • Female subjects who have positive serum pregnancy test taken within 14 days of study treatment
    • Female subjects of child-bearing potential who are unwilling to use highly effective contraception (e.g., combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives, intrauterine devices, bilateral tubal ligation, vasectomized partner, sexual abstinence or equivalent measures) for the duration of study treatment

12. Contraindication for all comparators:

    • Subjects with contraindications to all of the designated comparator drugs

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France, Germany, Italy, Mexico, United States
• Removed Location Countries: Australia

Administrative Information

• NCT Number: NCT02288897
• Other Study ID Numbers: PV-10-MM-31
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
• Study Sponsor: Provectus Biopharmaceuticals, Inc.
• Collaborators: Not Provided

Investigators

• Study Director: Eric Wachter, Ph.D.; Provectus Biopharmaceuticals, Inc.
• Principal Investigator: Sanjiv Agarwala, M.D.; St Luke's University Hospital and Health Network

• PRS Account: Provectus Pharmaceuticals
• Verification Date: September 2019